Ovarian cancer is a very chemosensitive tumor, but survival is poor due to
the emergence of drag resistance. It may be possible to overcome resistance
by using high dose chemotherapy supported by peripheral blood stem cell tr
ansplantation. A review of retrospective studies of dose-intensity and phas
e I/II high dose chemotherapy trials, and an analysis of the EBMT registry
data is used as evidence to support the case for dose-intensification in ov
arian cancer. As a result of this analysis there are now prospective random
ized trials of high dose chemotherapy in ovarian cancer.